Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Profit After Tax (2021 - 2025)

Valion Bio has reported Profit After Tax over the past 5 years, most recently at -$2.6 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 81.41% year-over-year to -$2.6 million; the TTM value through Sep 2025 reached -$7.5 million, down 16.56%, while the annual FY2024 figure was -$5.7 million, 31.4% up from the prior year.
  • Profit After Tax for Q3 2025 was -$2.6 million at Valion Bio, down from -$1.9 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$1.1 million in Q2 2021 and troughed at -$3.7 million in Q4 2021.
  • A 5-year average of -$2.0 million and a median of -$2.1 million in 2023 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: crashed 175.87% in 2022 and later soared 40.42% in 2024.
  • Year by year, Profit After Tax stood at -$3.7 million in 2021, then soared by 38.24% to -$2.3 million in 2022, then grew by 2.48% to -$2.2 million in 2023, then surged by 35.13% to -$1.5 million in 2024, then tumbled by 78.42% to -$2.6 million in 2025.
  • Business Quant data shows Profit After Tax for TIVC at -$2.6 million in Q3 2025, -$1.9 million in Q2 2025, and -$1.5 million in Q1 2025.